Zevra Therapeutics

Zevra Therapeutics is a company listed under the stock ticker KMPH (US).

View the org chart displaying its 22 main executives

Most searched biographies at Zevra Therapeutics

• Neil Mcfarlane, Chief Executive Officer and President
• John Bode, Director
• Thomas Anderson, Director

Popular executive movements at Zevra Therapeutics

• Rahsaan Thompson has joined the company as Chief Legal Officer, Secretary and Compliance Officer  (posted on June 26 2024).
• Alison Peters has joined the company as Chief People Officer  (posted on June 26 2024).
• Alvin Shih has joined the company as Director  (posted on January 24 2024).

Click here to view some more movements at Zevra Therapeutics

Create your alert
to follow the executive moves at Zevra Therapeutics.

Zevra Therapeutics has 1,840 competitors including Pfizer (United States (USA)), Johnson & Johnson (United States (USA)) and Sanofi (France).

Popular M&A news in Pharmaceuticals

• ANI Pharmaceuticals has announced the acquisition of Alimera Sciences  (posted on June 26 2024).
• Sun Pharma has acquired Taro Pharmaceutical (posted on June 25 2024).
• ONO Pharmaceutical has acquired Deciphera Pharmaceuticals (posted on June 12 2024).

Popular contacts in Pharmaceuticals

• Jean-Frédéric Paulsen - Executive Chairman of the Board at Ferring Pharmaceuticals
• Anat Ashkenazi - Senior Vice President and Chief Financial Officer (until Jul 31 2024) at Eli Lilly
• Danilo Cicmil - Supervisory Board Member at Galenika

Learn more about the Pharmaceuticals industry >

Press releases by Zevra Therapeutics

• KemPharm to Report Second Quarter 2022 Financial Results | KemPharm
• KemPharm to Present at the Canaccord Genuity 42nd Annual Growth Conference | KemPharm
• KemPharm to Participate in the 2022 Joint NNPDF-INPDA Conference and Meeting | KemPharm
• KemPharm Announces Research Affirming Serdexmethylphenidate’s Lower Potential for Abuse Featured in Peer-Reviewed Publication, Current Medical Research & Opinion | KemPharm
• Press Releases | KemPharm
• KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline | KemPharm
• KemPharm Reports First Quarter 2022 Financial Results and Corporate Updates | KemPharm
• Press Releases | KemPharm
• KemPharm to Present at Multiple Upcoming Investor Conferences | KemPharm
• KemPharm Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathic Hypersomnia (IH) | KemPharm
• View more press releases Close

Social media about Zevra Therapeutics

• Zevra Therapeutics on Wikipedia, Google News & Yahoo Finance
• Zevra Therapeutics on LinkedIn, Twitter & YouTube

Contact by email its executives including Thomas Anderson

Call Zevra Therapeutics at +1 319...

View the org chart

Register to receive your alert

Report an error